Iloperidone for Schizophrenia or Bipolar I Disorder in Adolescents
This study is looking at the safety of a medicine called iloperidone for teenagers aged 12 to 17 who have schizophrenia or bipolar I disorder. Researchers want to see how many participants experience side effects while taking iloperidone for up to one year. You could join if you are 12-17 years old, have been diagnosed with schizophrenia or bipolar I disorder, and are willing to participate. Your parent or guardian would also need to agree. The study plans to enroll 100 participants. The current recruitment status is unclear.
- Study design
- This is an open-label study, meaning everyone knows they are receiving iloperidone. It plans to enroll 100 participants aged 12-17.
- What's involved
- You would take iloperidone as an oral tablet for up to 52 weeks. Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will track side effects for one year after treatment begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
At a glance
Conditions
Where it's being run
9 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period.1 year